Sotagliflozin is an investigational drug that belongs to the class of medications known as sodium-glucose co-transporter 1 and 2 inhibitors (SGLT1/2 inhibitors). It is being studied for use in both type 1 diabetes and type 2 diabetes management. Clinical trials and research on Sotagliflozin have shown promising results, particularly in its potential effectiveness when used […]
An enzyme that plays a major role in the development of cancer and type 2 diabetes also activates a protein that contributes to Parkinson’s, researchers say, potentially providing a new research avenue that could someday help treat all three diseases. Read more
People who reported eating two or more servings per week of oily fish, such as sardines, had a 22% lower risk of developing type 2 diabetes, according to a large study in the U.K. Read more
The Bydureon BCise once-weekly injection has received FDA approval for use in children and teens age 10-17 after trial results showed it significantly reduced blood sugar in adolescents. This is the first once-weekly dose of the GLP-1 receptor agonist drug class approved for older children. Read more
GLP-1 RAs are a class of diabetes medication that includes drugs like Trulicity, Ozempic, and Byetta. Drugs in this class have been shown to have a beneficial effect on heart health. Researchers examined whether GLP-1 RAs’ effectiveness in reducing blood glucose (HbA1c) levels is responsible for the reduction in cardiovascular risk associated with the medications. […]
Tirzepatide, a new once-weekly GIP/GLP-1 medication, is now in phase 3 testing for blood glucose management and chronic weight management in individuals with type 2 diabetes. GIP is a hormone that may help GLP-1 receptor agonists work better, and has been found in early testing to reduce food intake while increasing energy expenditure, resulting in […]
A study found that the development of type 2 diabetes was reduced by 32% in participants who took the SGLT-2 inhibitor medication dapagliflozin instead of placebo, suggesting there may be a possible prevention, as well as treatment, role for this diabetes drug. Read more
Teenagers with overweight or obesity may be more likely to develop type 2 diabetes or have a heart attack when they reach their 30s and 40s, even if they lose weight in adulthood, a recent study says. Read more
A major genetic study has identified more regions of the genome linked to type 2 diabetes-related traits as a result of including multi-ethnic participants than if the research had been conducted only in Europeans, the researchers say. Previously, almost 90% of this type of genetic research had been conducted in Europeans. Read more
Pharma company Eli Lilly recently announced results of clinical trials for their new diabetes drug, Tirzepatide. The drug acts by mimicking the functions of incretin hormones, and would be a new type of medication to treat type 2 diabetes. It shows promise for improving blood glucose levels and helping achieve weight reduction. Read more
Long-term use of the common diabetes drug metformin use may have a protective effect on breast cancer risk for women with type 2 diabetes, researchers say. However, the effect of metformin depends on the breast cancer subtype. Read more
The FDA has cleared The Bigfoot Unity AI Diabetes Management System by Bigfoot Biomedical, an artificially intelligent insulin pen cap, for use in type 1 and type 2 diabetes patients aged 12 or older. The device has the potential to make insulin dosing much less burdensome for many patients. Read more
A new study examined what motivates type 2 diabetes patients’ preferences for either once-daily oral or once-weekly injectable medication. They found that initially, diabetes patients expressed a preference for the once-daily oral medication at approximately 3:1. However, many patients had a different opinion after learning more about the advantages and disadvantages of the once-weekly shot. […]
The COVID-19 pandemic has made managing their diabetes more difficult for many Americans, new research says. 19% of Americans with diabetes skipped at least one medical appointment due to fear of contracting the virus. Almost a quarter say that managing their diabetes has been difficult due to the pandemic, while 17% say they have developed […]
While insulin is the standard treatment for type 1 diabetes, it is also used for type 2 diabetes patients who are unable to reach their glycemic target with other medications. As the number of patients with type 2 prescribed insulin is growing, researchers sought to understand whether the risk for hypoglycemia associated with insulin could […]
Indexes of insulin sensitivity are a practical method for assessing type 2 diabetes risk without more complicated tests. However, while studies have compared the effectiveness of various indexes in predicting type 2 diabetes in whites, African Americans, Hispanic Americans, and other ethnicities, studies among the Asian population have been lacking. Read more
A new study conducted among 4,000 young men who had a stutter, between the ages of 16- and 20-years old, and living in Israel, found that teenagers who stutter may have a higher likelihood of developing early-onset type 2 diabetes. One explanation is that the anxiety a person may experience about their speech impediment could […]
Many patients with chronic kidney disease are at a higher risk for severe kidney and heart health issues. The DAPA-CKD trial was designed to see the impact of Dapagliflozin Propanediol, which is sold under the brand name Farxiga, in patients with and without type 2 diabetes who had chronic kidney disease. Read more
People who have type 2 diabetes often have reduced muscle strength, with the ability of the muscles to take up glucose impaired. Researchers have found that a particular gene that normally plays an important role in muscle regeneration is “silenced” in people who have type 2 diabetes. The discovery may lead to future new treatments. […]
A recent study says that the access of people with type 2 diabetes to sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment has significant ethnic, gender and socioeconomic disparities, with women, Black or Asian patients less likely to receive SGLT-2 inhibitor treatment. Read more